Kalinorm

Kalinorm

Active ingredient (INN)
Potassium chloride, dextrose.

Pharmaceutical form
Solution for infusion

Ingredients
100 ml solution contains:
Potassium chloride – 0.5 g
Anhydrous glucose – 5.0 g

Indications
Potassium deficiency caused by:

• Diabetes
• Prolonged diarrhea and\or vomiting
• Treatment by certain antihypertensive drugs (diuretics)
• Glucocorticosteroid therapy
• Treatment and prevention of digitalis intoxication
• Arrhythmia prevention in patients with acute myocardial infarction

Administration and Dosage

• Potassium chloride solution is administered drip intravenously by intravenous drip at a rate of 20-30 drops per minute. The dose and treatment schedule are determined individually.
• Before use heat KALINORM solution up to 36 – 38 degrees.
• To be injected preferably into large peripheral veins.

Contraindications

• Hyperkalemia, complete AV block, adrenal insufficiency, chronic renal failure, the use of potassium-sparing diuretics during concomitant therapy, metabolic disorders (acidosis, hypovolemic hyponatremia), erosive and ulcerative digestive tract disorders, patients under 18 years old (efficacy and safety have not been confirmed).
• Use with caution: during pregnancy and breastfeeding.

Drug interactions

• Pharmaceutically compatible with cardiac glycoside solutions. Enhances negative dromo- and bathmotropic effects of antiarrhythmic agents.
• As a part of the polarizing mixture (in combination with insulin and dextrose) contributes to the cardiac rhythm normalization in myocardial infarction, ectopic arrhythmias and cardiac glycoside overdoses.
• Eliminates hypokalemia, caused by glucocorticosteroids, topical corticosteroids and diuretics. Beta-adrenoblockers, cyclosporine, potassium-sparing diuretics, heparin, angiotensin converting enzyme inhibitors, NSAIDs can increase the risk of hyperkalemia.

Special Instructions

• During the treatment period, the potassium concentrations in the blood serum and ECG should be controlled; in treating hypokalemia - control of acid-base status is necessary. Safety and effectiveness of the drug in children have not been determined yet.
• During breastfeeding, it is necessary to solve the problem of breastfeeding discontinuation.
• A diet with a high content of sodium ions increases the excretion of potassium ions from the body.
• One should remember that hyperkalemia that leads to death can develop quickly and be asymptomatic. If administration of the drug is necessary during the pregnancy period, one should compare the expected benefits for the mother and the potential risk for the fetus.